MannKind Corporation (NASDAQ:MNKD) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.11), Briefing.com reports. The company had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.56 million. MannKind Corporation had a net margin of 71.60% and a negative return on equity of 24.93%. The business’s revenue for the quarter was down 98.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.30 earnings per share.

MannKind Corporation (NASDAQ MNKD) traded up $0.02 during trading on Tuesday, reaching $3.25. 3,140,000 shares of the company traded hands, compared to its average volume of 13,910,000. MannKind Corporation has a 52-week low of $0.67 and a 52-week high of $6.96. The firm has a market capitalization of $373.34, a PE ratio of 6.04 and a beta of 3.10. The company has a current ratio of 0.59, a quick ratio of 0.56 and a debt-to-equity ratio of -0.48.

WARNING: “MannKind Corporation (MNKD) Issues Quarterly Earnings Results” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/07/mannkind-corporation-mnkd-issues-quarterly-earnings-results.html.

In other news, Director Kent Kresa acquired 166,600 shares of the business’s stock in a transaction that occurred on Friday, October 13th. The stock was purchased at an average cost of $6.00 per share, for a total transaction of $999,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is currently owned by company insiders.

Several equities analysts have issued reports on the stock. Maxim Group reaffirmed a “hold” rating on shares of MannKind Corporation in a report on Wednesday, November 1st. HC Wainwright reissued a “buy” rating on shares of MannKind Corporation in a research note on Tuesday, October 24th. ValuEngine downgraded shares of MannKind Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Finally, Zacks Investment Research raised shares of MannKind Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $0.92.

About MannKind Corporation

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Earnings History for MannKind Corporation (NASDAQ:MNKD)

Receive News & Stock Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related stocks with our FREE daily email newsletter.